NervGen Pharma Corp.

Recent News

  • NervGen Pharma Announces Upgrade to the OTCQX Best Market in the U.S.

    Vancouver, British Columbia--(Newsfile Corp. - June 10, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has qualified to trade its common shares ...

    2019-06-10 7:00 AM ET
  • NervGen Pharma Presenting at the 9th Annual LD Micro Invitational

    Vancouver, British Columbia--(Newsfile Corp. - June 4, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that Ernest Wong, NervGen Pharma's President ...

    2019-06-04 3:30 PM ET
  • NervGen Pharma Engages Torrey Hills Capital for Investor Relations

    Vancouver, British Columbia--(Newsfile Corp. - June 3, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has engaged San ...

    2019-06-03 8:30 AM ET
  • NervGen Pharma Appoints Dr. Denis Bosc as Vice President of Manufacturing

    Vancouver, British Columbia--(Newsfile Corp. - May 30, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has appointed Denis Bosc, ...

    2019-05-30 9:00 AM ET
  • NervGen Pharma Commences Trading on OTCQB

    Vancouver, British Columbia--(Newsfile Corp. - May 3, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage including spinal cord and peripheral nerve injury, today announced that in addition to trading ...

    2019-05-03 9:00 AM ET
  • NervGen Pharma to Ring the Opening Bell of Toronto Stock Exchange

    Vancouver, British Columbia--(Newsfile Corp. - May 1, 2019) -  NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage including spinal cord and peripheral nerve injury, today announced that the Company will ring the opening bell ...

    2019-05-01 2:26 PM ET
  • NervGen Pharma's Patent Estate Grows with the Addition of US Patents for Its Groundbreaking Nerve Regeneration Technology

    Vancouver, British Columbia--(Newsfile Corp. - April 24, 2019) - NervGen Pharma Corp. ("NervGen"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, announces the issuance by the U.S. Patent and Trademark Office of two new patents protecting the development and commercialization of protein tyrosine ...

    2019-04-24 9:00 AM ET
  • Amended: NervGen Pharma Increases Private Placement to $740,000

    Vancouver, British Columbia--(Newsfile Corp. - April 23, 2019) - NervGen Pharma Corp. ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has increased the amount of its non-brokered private placement announced on March 14, 2019 ...

    2019-04-23 6:08 PM ET